TV News LIES

Wednesday, Jul 27th

Last update05:20:13 AM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.

More...


Most Recent Related Stories...


Medicare safeguard overwhelmed by pricey drugs

Medicare drug costsA safeguard for Medicare beneficiaries has become a way for drugmakers to get paid billions of...

Seven US cities losing their doctors

Cities losing doctorsAs the U.S. population continues to grow — and age — demand for health care services...

Johnson & Johnson subsidiary pays $18 million to U.S. in settlement

Johnson & Johnson pays $18mJohnson & Johnson's subsidiary Acclarent, paid $18 million to resolve allegations the company marketed a medical...

$1 Billion Health Care Fraud Took Advantage Of Medicare In Florida

Miami Medicaid fraudThe Justice Department calls is the largest criminal health care fraud case ever brought against individual...
 
America's # 1 Enemy
Tee Shirt
& Help Support TvNewsLIES.org!
TVNL Tee Shirt
 
TVNL TOTE BAG
Conserve our Planet
& Help Support TvNewsLIES.org!
 
Get your 9/11 & Media
Deception Dollars
& Help Support TvNewsLIES.org!
 
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!